XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassing the pre-set efficacy threshold. The study, funded by the French National Cancer Institute, also found a significant survival benefit in patients with right-sided tumors, a subgroup with poor prognosis. Vilamakitug demonstrated good safety and treatment adherence, supporting further clinical development towards approval.
XBiotech's Phase II TASKIN study showed a 12-month overall survival rate of 61.3% for refractory metastatic colorectal cancer patients. For readers following the health sector, here is Pluang's market snapshot as of Oct 20, 2026 05:21 WIB: out of 150 priced US health stocks, 81 rose and 67 fell. Notable movers include XRAY at USD 8.84 (+4.74%), MRNA at USD 227.72 (+4.45%) with 66% buy order activity, and IOVA at USD 14.20 (+4.26%).
XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
